Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

Lucio Crinò, Giulio Metro
European Respiratory Review 2014 23: 79-91; DOI: 10.1183/09059180.00008913
Lucio Crinò
Division of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lucio.crino@ospedale.perugia.it
Giulio Metro
Division of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Molecular pathways underlying angiogenesis. A: Tumour cells produce vascular endothelial growth factor (VEGF)-A and other angiogenic factors, such as basic fibroblast growth factor (bFGF), angiopoietins, interleukin-8, placental growth factor and VEGF-C. These stimulate resident endothelial cells to proliferate and migrate. B: An additional source of angiogenic factors is the stroma. This is a heterogeneous compartment, comprising fibroblastic, inflammatory and immune cells. Recent studies indicate that tumour-associated fibroblasts produce chemokines, such as stromal cell-derived factor (SDF)-1, which may recruit bone-marrow-derived angiogenic cells (BMC). VEGF-A or placental growth factor may also recruit BMC. Tumour cells may also release stromal cell-recruitment factors, such as platelet-derived growth factor (PDGF)-A, PDGF-C or transforming growth factor (TGF)-β. A well-established function of tumour-associated fibroblasts is the production of growth/survival factor for tumour cells, such as epidermal growth factor (EGF) receptor ligands, hepatocyte growth factor and heregulin. C: Endothelial cells produce PDGF-B, which promotes recruitment of pericytes in the microvasculature after activation of PDGF receptor-β. HGF: hepatocyte growth factor. Reproduced from [10] with permission.

Tables

  • Figures
  • Table 1. Recent phase III trials assessing antiangiogenic agents in a first-line setting
    Agent and study name [ref.]Target (s)Study designOverall response rateProgression-free survivalOverall survival
    Monoclonal antibodies
        Bevacizumab; ECOG 4599 [14]VEGFStage IIIB/IV non-squamous NSCLC Patients randomised to: carboplatin/paclitaxel (n = 444) or carboplatin/paclitaxel + bevacizumab (15 mg·kg−1; n = 434) Primary end-point: overall survivalCarboplatin/paclitaxel: 15% Carboplatin/paclitaxel + bevacizumab: 35% (p<0.001)Carboplatin/paclitaxel: 4.5 months Carboplatin/paclitaxel + bevacizumab: 6.2 months HR 0.66 (95% CI 0.57–0.77); p<0.001Carboplatin/paclitaxel: 10.3 months Carboplatin/paclitaxel + bevacizumab: 12.3 months HR 0.79 (95% CI 0.67–0.92); p = 0.003
        Bevacizumab; AVAiL [21, 22]VEGFStage IIIB/IV non-squamous NSCLC Patients randomised to: cisplatin/gemcitabine (n = 347), cisplatin/gemcitabine + bevacizumab (7.5 mg·kg−1; n = 345) or cisplatin/gemcitabine + bevacizumab (15 mg·kg−1; n = 351) Primary end-point: progression-free survivalCisplatin/gemcitabine: 20.1% Cisplatin/gemcitabine + bevacizumab (7.5 mg·kg−1): 34.1% Cisplatin/gemcitabine + bevacizumab (15 mg·kg−1): 30.4% (p<0.0001 and p = 0.0023, respectively)Cisplatin/gemcitabine: 6.1 months Cisplatin/gemcitabine + bevacizumab (7.5 mg·kg−1): 6.7 months Cisplatin/gemcitabine + bevacizumab (15 mg·kg−1): 6.5 months HR 0.75 (95% CI 0.62–0.91); p = 0.003 and HR 0.92 (95% CI 0.68–0.98); p = 0.03, respectivelyCisplatin/gemcitabine: 13.1 months Cisplatin/gemcitabine + bevacizumab (7.5 mg·kg−1): 13.6 months Cisplatin/gemcitabine + bevacizumab (15 mg·kg−1): 13.4 months HR 0.92 (95% CI 0.78–1.11); p = 0.420 and HR 1.03 (95% CI 0.86–1.23); p = 0.761, respectively
    Multi-targeted antiangiogenic orally administered TKIs
        Cediranib; BR24 [23]VEGFR-1–3, PDGFR-β, FGFR-1 and c-kitStage IIIB/IV NSCLC all histologies Patients randomised to: carboplatin/paclitaxel (n = 125) or carboplatin/paclitaxel + cediranib (30 mg·day−1; n = 126) Primary end-point: progression-free survivalCarboplatin/paclitaxel: 16% Carboplatin/paclitaxel + cediranib: 38% (p<0.0001)Carboplatin/paclitaxel: 5.0 months Carboplatin/paclitaxel + cediranib: 5.6 months HR 0.77 (95% CI 0.56–1.08); p = 0.13Carboplatin/paclitaxel: 10.1 months Carboplatin/paclitaxel + cediranib: 10.5 months HR 0.78 (95% CI 0.57–1.06); p = 0.11
        Cediranib; BR29 [24]VEGFR-1–3, PDGFR-β, FGFR-1 and c-kitStage IIIB/IV NSCLC all histologies Patients randomised to: carboplatin/paclitaxel or carboplatin/paclitaxel + cediranib (20 mg·day−1) Primary end-point: overall survivalCarboplatin/paclitaxel: 34% Carboplatin/paclitaxel + cediranib: 52% (p = 0.001)Carboplatin/paclitaxel: 5.5 months Carboplatin/paclitaxel + cediranib: 5.5 months HR 0.91 (95% CI 0.71–1.18); p = 0.5Carboplatin/paclitaxel: 12.1 months Carboplatin/paclitaxel + cediranib: 12.2 months HR 0.95 (95% CI 0.69–1.30); p = 0.74
        Sorafenib; ESCAPE [25]VEGFR-2–3, PDGFR-β, c-kit, Raf and flt-3Stage IIIB/IV NSCLC all histologies Patients randomised to: carboplatin/paclitaxel (n = 462) or carboplatin/paclitaxel + sorafenib (400 mg; n = 464) Primary end-point: overall survivalCarboplatin/paclitaxel: 27% Carboplatin/paclitaxel + sorafenib: 24% (p = 0.102)Carboplatin/paclitaxel: 5.4 months Carboplatin/paclitaxel + sorafenib: 4.6 months HR 0.99 (95% CI 0.84–1.16); p = 0.433Carboplatin/paclitaxel: 10.6 months Carboplatin/paclitaxel + sorafenib: 10.7 months HR 1.15 (95% CI 0.94–1.41); p = 0.915
        Sorafenib; NExUS [26]VEGFR-2–3, PDGFR-β, c-kit, Raf and flt-3Stage IIIB/IV non-squamous NSCLC Patients randomised to: gemcitabine/cisplatin (n = 387) or gemcitabine/cisplatin + sorafenib (400 mg; n = 385) Primary end-point: overall survivalGemcitabine/cisplatin: 26% Gemcitabine/cisplatin + sorafenib: 28% (p = 0.27)Gemcitabine/cisplatin: 5.5 months Gemcitabine/cisplatin + sorafenib: 6.0 months HR 0.83 (95% CI 0.71–0.97); p = 0.008Gemcitabine/cisplatin: 12.5 months Gemcitabine/cisplatin + sorafenib: 12.4 months HR 0.98 (65% CI 0.83–1.16); p = 0.401
        Motesanib; MONET1 [27]VEGFR-1–3, PDGFR-β, c-kit and RETStage IIIB/IV non-squamous NSCLC Patients randomised to: carboplatin/paclitaxel (n = 549) or carboplatin/paclitaxel + motesanib (125 mg; n = 541) Primary end-point: overall survivalCarboplatin/paclitaxel: 26% Carboplatin/paclitaxel + motesanib: 40% (p<0.001)Carboplatin/paclitaxel: 5.4 months Carboplatin/paclitaxel + motesanib: 5.6 months HR 0.79 (95% CI 0.61–0.98); p<0.001Carboplatin/paclitaxel: 11.0 months Carboplatin/paclitaxel + motesanib: 13.0 months HR 0.90 (95% CI 0.78–1.04); p = 0.14
    Vascular disrupting agents
        Vadimezan; ATTRACT-1 [28]Stage IIIB/IV NSCLC all histologies Patients randomised to: carboplatin/paclitaxel (n = 650) or carboplatin/paclitaxel + vadimezan (1800 mg·m−2; n = 649) Primary end-point: overall survivalCarboplatin/paclitaxel: 25% Carboplatin/paclitaxel + vadimezan: 25% (p = 1.0)Carboplatin/paclitaxel: 5.5 months Carboplatin/paclitaxel + vadimezan: 5.5 months HR 1.04 (95% CI 0.91–1.19); p = 0.727Carboplatin/paclitaxel: 12.7 months Carboplatin/paclitaxel + vadimezan: 13.4 months HR 1.01 (95% CI 0.85–1.19); p = 0.535
    • ECOG: Eastern Cooperative Oncology Group; AVAiL: Avastin in Lung Cancer; TKI: tyrosine kinase inhibitor; ESCAPE: Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC; NExUS: NSCLC research Experience Utilising Sorafenib; MONET1: Motesanib NSCLC Efficacy and Tolerability Study; ATTRACT-1: Antivascular Targeted Therapy: Researching ASA404 in Cancer Treatment; VEGF: vascular endothelial growth factor; VEGFR: VEGF receptor; PDGFR: platelet-derived growth factor receptor; FGFR: fibroblast growth factor receptor; RET: Rearranged during Transfection; NSCLC: nonsmall cell lung cancer; HR: hazard ratio.

  • Table 2. Recent phase III trials assessing antiangiogenic agents in a second- or third-line setting
    Agent and study name [ref.]Target (s)Study designOverall response rateProgression-free survivalOverall survival
    Multi-targeted antiangiogenic orally administered TKIs
        Nintedanib; LUME-Lung 1[44]VEGF-1–3, PDGF-α and β, and FGFR-1–3Stage IIIB/IV NSCLC all histologies Patients randomised to: docetaxel (n = 659) or docetaxel + nintedanib (200 mg twice daily; n = 655) Primary end-point: progression-free survivalOverall response rate not reported DCR was significantly greater in the docetaxel + nintedanib arm in patients with adenocarcinoma (p<0.0001)Docetaxel: 2.7 months Docetaxel + nintedanib: 3.4 months HR 0.79 (CI 0.68–0.92); p = 0.002In patients with adenocarcinoma: Docetaxel: 10.3 months Docetaxel + nintedanib: 12.6 months HR 0.83; p = 0.036 In overall population: Docetaxel: 9.1 months Docetaxel + nintedanib: 10.1 months HR 0.94; p = 0.272
        Nintedanib; LUME-Lung 2 [45]VEGF-1–3, PDGF-α and β, and FGFR-1–3Stage IIIB/IV non-squamous NSCLC Patients randomised to: pemetrexed (n = 360) or pemetrexed + nintedanib (200 mg twice daily; n = 353) Primary end-point: progression-free survivalNo difference in overall response rate between pemetrexed and pemetrexed + nintedanib (9%) Pemetrexed: DCR 53% Pemetrexed + nintedanib: DCR 61% (p = 0.039)Pemetrexed: 3.6 months Pemetrexed + nintedanib: 4.4 months HR 0.83 (95% CI 0.7–0.99); p = 0.04No significant difference (median values NR)
        Vandetanib; ZODIAC [46]VEGFR-1 and -2, RET and EGFRStage IIIB/IV NSCLC all histologies Patients randomised to: docetaxel (n = 697) or docetaxel + vandetanib (100 mg·day−1; n = 694) Primary end-point: progression-free survivalDocetaxel: 10% Docetaxel + vandetanib: 17% (p = 0.0001)Docetaxel: 3.2 months Docetaxel + vandetanib: 4.0 months HR 0.79 (97.6% CI 0.70–0.90); p<0.0001Docetaxel: 10.0 months Docetaxel + vandetanib: 10.6 months HR 0.91 (97.5% CI 0.78–1.07); p = 0.196
        Vandetanib; ZEAL [47]VEGFR-1 and -2, RET and EGFRStage IIIB/IV NSCLC all histologies Patients randomised to: pemetrexed (n = 278) or pemetrexed + vandetanib (100 mg·day−1; n = 256) Primary end-point: progression-free survivalPemetrexed: 8% Pemetrexed + vandetanib: 19% (p<0.001)Pemetrexed: 11.9 weeks Pemetrexed + vandetanib: 17.6 weeks HR 0.86 (97.6% CI 0.69–1.06); p = 0.108Pemetrexed: 9.2 months Pemetrexed + vandetanib: 10.5 months HR 0.86 (97.5% CI 0.65–1.13); p = 0.219
        Vandetanib; ZEPHYR [48]VEGFR-1 and -2, RET and EGFRStage IIIB/IV NSCLC all histologies Pre-treated with EGFR inhibitor and one or two chemotherapy regimens Patients randomised to: placebo (n = 307) or vandetanib (300 mg·day-1; n = 617) Primary end-point: overall survivalPlacebo: 0.7% Vandetanib: 2.6% (p = 0.028)Placebo: 1.8 months Vandetanib: 1.9 months HR 0.63 (95.2% CI 0.54–0.74); p<0.001Placebo: 7.8 months Vandetanib: 8.5 months HR 0.95 (95.2% CI 0.81–1.11); p = 0.527
        Vandetanib; ZEST [49]VEGFR-1 and -2, RET and EGFRStage IIIB/IV NSCLC all histologies Patients randomised to: erlotinib (150 mg·day−1; n = 617) or vandetanib (300 mg·day−1; n = 623) Primary end-point: progression-free survivalErlotinib: 12% Vandetanib: 12% (p = 0.98)Erlotinib: 2.0 months Vandetanib: 2.6 months HR 0.98 (95.2% CI 0.87–1.10); p = 0.721Erlotinib: 7.8 months Vandetanib: 6.9 months HR 1.01 (95.1% CI 0.89–1.16); p = 0.830
        Sorafenib; MISSION [50]VEGFR-2–3, PDGFR-β, c-kit, Raf and flt-3Stage IIIB/IV non-squamous NSCLC Patients randomised to: placebo (n = 353) or sorafenib (400 mg twice daily; n = 350) Primary end-point: overall survivalPlacebo: 0.9% Sorafenib: 4.9% (p<0.001)Placebo: 43 days Sorafenib: 84 days HR 0.61; p<0.0001Placebo: 253 days Sorafenib: 248 days HR 0.99; p = 0.4687
        Sunitinib [51]VEGF-1–3, PDGFR-α and β, and RETStage IIIB/IV NSCLC all histologies Patients randomised to: erlotinib (150 mg·day−1; n = 480) or erlotinib + sunitinib (37.5 mg·day−1; n = 480) Primary end-point: overall survivalErlotinib: 6.9% Erlotinib + sunitinib: 10.6% (p = 0.048)Erlotinib: 2.0 months Erlotinib + sunitinib: 3.6 months HR 0.81 (95% CI 0.70–0.94); p = 0.0023Erlotinib: 8.5 months Erlotinib + sunitinib: 9.0 months HR 0.92 (95% CI 0.80–1.07); p = 0.139
    Monoclonal antibodies, decoy receptors
        Bevacizumab; BeTa [52]VEGFStage IIIB/IV NSCLC all histologies Patients randomised to: erlotinib (150 mg·day−1; n = 317) or erlotinib + bevacizumab (n = 319) Primary end-point: progression-free survivalErlotinib: 6% Erlotinib + bevacizumab: 13% (p-value NR)Erlotinib: 1.7 months Erlotinib + bevacizumab: 3.4 months HR 0.62 (95% CI 0.52–0.75); p-value NRErlotinib: 9.2 months Erlotinib + bevacizumab: 9.3 months HR 0.97 (95% CI 0.80–1.18); p = 0.758
        Aflibercept; VITAL [53]VEGFNon-squamous NSCLC Patients randomised to: docetaxel (n = 457) or docetaxel + aflibercept (6 mg·day−1; n = 456) Primary end-point: overall survivalDocetaxel: 8.9% Docetaxel + aflibercept: 23.3% (p<0.001)Docetaxel: 4.1 months Docetaxel + aflibercept: 5.2 months HR 0.82 (95% CI 0.72–0.94); p = 0.0035Docetaxel: 10.4 months Docetaxel + aflibercept: 10.1 months HR 1.01 (95% CI 0.87–1.17); p = 0.9
    • TKI: tyrosine kinase inhibitor; ZODIAC: Zactima in Combination with Docetaxel in NSCLC; ZEAL : Zactima Efficacy with Alimta in Lung Cancer; ZEPHYR: Zactima Efficacy Trial for NSCLC Patients with a History of EGFR-TKI and Chemoresistance; ZEST: Zactima Efficacy Study versus Tarceva; VEGF: vascular endothelial growth factor; PDGF: platelet-derived growth factor; FGFR: fibroblast growth factor receptor; VEGFR: VEGF receptor; EGFR: epidermal growth factor receptor; PDGFR: PDGF receptor; NSCLC: nonsmall cell lung cancer; NR: not reported; DCR: disease control rate; HR: hazard ratio.

PreviousNext
Back to top
View this article with LENS
Vol 23 Issue 131 Table of Contents
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
Lucio Crinò, Giulio Metro
European Respiratory Review Mar 2014, 23 (131) 79-91; DOI: 10.1183/09059180.00008913

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
Lucio Crinò, Giulio Metro
European Respiratory Review Mar 2014, 23 (131) 79-91; DOI: 10.1183/09059180.00008913
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Introduction
    • Antiangiogenic agents in the first-line setting
    • Antiangiogenic agents in a relapsed/refractory setting
    • Other investigational antiangiogenic agents in NSCLC
    • Outlook for antiangiogenic therapy in NSCLC
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary pharmacology and therapeutics
  • Lung cancer
  • Lung biology and experimental studies
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Risk factors for asthma exacerbations during pregnancy
  • The role of cigarette smoke in COPD
  • Combining small-molecule inhibitors and DOACs in patients with NSCLC
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2022 by the European Respiratory Society